0.05Open0.15Pre Close10 Volume55 Open Interest5.00Strike Price50.00Turnover146.17%IV36.05%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0481Delta0.0447Gamma154.80Leverage Ratio-0.0076Theta-0.0002Rho-7.44Eff Leverage0.0015Vega
Mesoblast Stock Discussion
Mesoblast (MESO) has released an update.
Mesoblast Limited has reported significant progress in its discussions with the FDA, receiving guidance on licensure paths for its innovative therapies, remestemcel-L for pediatric graft versus host disease, and rexlemestrocel-L for end-stage heart failure. The company is poised to resubmit its Biologics License Application for remestemcel-L and seeks an accelerated approval for ...
No comment yet